Industry News
Share your love
Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa
(Image Credit: AdobeStock/Dmitrii Kotin) Beacon Therapeutics recently revealed topline data results for 2 of the company’s phase 2 trials—SKYLINE and DAWN, both investigating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).1 The data was presented during the 2025…
Amir Kashani on biomarkers for Alzheimer disease
(Image credit: AdobeStock/Pixel Matrix) Amir H. Kashani, MD, PhD, is a professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland. In an interview with Ophthalmology Times, Kashani discussed a research paper on OCT-A angiography’s…
Opus Genetics doses first patient in LYNX-3, phase 3 trial of phentolamine ophthalmic solution 0.75%
(Image Credit: AdobeStock/svetlanais) Opus Genetics has dosed the first patient in LYNX-3, its pivotal phase 3 clinical trial of phentolamine ophthalmic solution 0.75% in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Night-vision disturbances, which…
Contivue port delivery platform for nAMD receives CE mark
(Image credit: ©Symbiot/AdobeStock) The European Union has granted the EU CE mark to Roche’s port delivery platform, Contivue.1 This platform contains Susvimo (ranibizumab injection) 100 mg/mL, which is currently under review with the European Medicines Agency (EMA) for the treatment…
Creation of OpZira Inc. announced following Alcon’s acquisition of LumiThera
(Image credit: AdobeStock) The company OpZira Inc. has launched to advance ophthalmic diagnostics. The company plans to deliver innovative technologies with the ability to enhance the detection and monitoring of ocular disease, which can empower clinicians. Clark Tedford, PhD, President…
Ophthalmic Devices Market Surges to USD 100.2 Billion by 2033, Propelled by 6.4% CAGR
\n \n The Ophthalmic Devices Market is witnessing robust expansion driven by rising demand for advanced eye care solutions, growing prevalence of vision disorders, and a rapidly aging population. Technological advancements such as AI-driven diagnostics, minimally invasive surgical systems, and…
Outlook Therapeutics requests Type A meeting with FDA following second CRL for ONS-5010
(Image Credit: AdobeStock) Outlook Therapeutics has requested a Type A meeting with the US Food and Drug Administration following the agency issuing a complete response letter (CRL) to its biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment…
The state of retina at ASRS 2025 with Charles C. Wykoff, MD, PhD, and Kevin Quinn
(Image credit: AdobeStock/vetrana) The annual scientific meeting of the American Society of Retina Specialists (ASRS) was held in Long Beach, California from July 30 through August 2, 2025. At this event, researchers and experts in the retina field shared data…
EyeCool Therapeutics appoints Vance Thompson, MD, to board of directors
EyeCool Therapeutics has appointed Vance Thompson, MD, founder of Vance Thompson Vision and immediate past president of the American Society of Cataract and Refractive Surgery (ASCRS), to the company’s board of directors. Thompson has personally performed more than 100,000 vision…
Vicky Demas on the importance of simplifying retinal screenings and incorporating AI
Vicky Demas, PhD, CEO of identifeye HEALTH, spoke to Ophthalmology Times about the company’s recent FDA registration and the it’s innovative retinal imaging technology. The company formally registered with the FDA, enabling them to market their device in the United…